fasudil has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 1 |
| Yasumura, D | 1 |
| Ma, AA | 1 |
| Matthes, MT | 1 |
| Yang, H | 1 |
| Nielson, G | 1 |
| Huang, Y | 1 |
| Szoka, FC | 1 |
| Lavail, MM | 1 |
| Diamond, MI | 1 |
1 other study available for fasudil and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Electroretinography; | 2013 |